Cost-effectiveness of irinotecan in advanced colorectal cancer [2]

Annals of Oncology

Volumn 11, Issue 7, 2000, Pages 899-900

  Trippoli, S ^a   Vaiani, M ^a   Cattel, F ^a   Messori, A ^a  

^a CAREGGI UNIVERSITY HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; IRINOTECAN;

ADVANCED CANCER; CANCER SURVIVAL; COLORECTAL CANCER; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG COST; HEALTH CARE COST; LETTER; PRIORITY JOURNAL;

EID: 0033816809     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008387526321     Document Type: Letter

References (4)

1. A retrospective cost-effectiveness analysis of interferon as adjuvant therapy in high-risk resected cutaneous melanoma
2. Pharmacoeconomic profile of paclitaxel as a first-line treatment for patients with advanced ovarian carcinoma. A lifetime cost-effectiveness analysis
3. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial
4. Cost-effectiveness of second-line treatment with irinotecan or infusional 5-fluorouracil in metastatic colorectal cancer